<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">660</journal-id>
        <journal-id journal-id-type="pmc-domain">jco</journal-id>
        <journal-id journal-id-type="publisher-id">JCO</journal-id>
        <journal-title-group>
          <journal-title>Journal of Clinical Oncology</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0732-183X</issn>
        <issn pub-type="epub">1527-7755</issn>
        <publisher>
          <publisher-name>American Society of Clinical Oncology</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC3753703</article-id>
        <article-id pub-id-type="pmcid-ver">PMC3753703.1</article-id>
        <article-id pub-id-type="pmcaid">3753703</article-id>
        <article-id pub-id-type="pmcaiid">3753703</article-id>
        <article-id pub-id-type="pmid">23897969</article-id>
        <article-id pub-id-type="doi">10.1200/JCO.2012.46.5740</article-id>
        <article-id pub-id-type="publisher-id">65740</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="hwp-journal-coll">
            <subject>To16</subject>
          </subj-group>
          <subj-group subj-group-type="heading">
            <subject>ORIGINAL REPORTS</subject>
            <subj-group>
              <subject>Translational Oncology</subject>
            </subj-group>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer</article-title>
          <alt-title alt-title-type="short">Actionable Drug Targets in High-Grade Bladder Cancer</alt-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Iyer</surname>
              <given-names initials="G">Gopa</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Al-Ahmadie</surname>
              <given-names initials="H">Hikmat</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hanrahan</surname>
              <given-names initials="AJ">Aphrothiti J.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ostrovnaya</surname>
              <given-names initials="I">Irina</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Balar</surname>
              <given-names initials="AV">Arjun V.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kim</surname>
              <given-names initials="PH">Philip H.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lin</surname>
              <given-names initials="O">Oscar</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Weinhold</surname>
              <given-names initials="N">Nils</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sander</surname>
              <given-names initials="C">Chris</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zabor</surname>
              <given-names initials="EC">Emily C.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Janakiraman</surname>
              <given-names initials="M">Manickam</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Garcia-Grossman</surname>
              <given-names initials="IR">Ilana R.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Heguy</surname>
              <given-names initials="A">Adriana</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Viale</surname>
              <given-names initials="A">Agnes</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bochner</surname>
              <given-names initials="BH">Bernard H.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Reuter</surname>
              <given-names initials="VE">Victor E.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bajorin</surname>
              <given-names initials="DF">Dean F.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Milowsky</surname>
              <given-names initials="MI">Matthew I.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Taylor</surname>
              <given-names initials="BS">Barry S.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
            <xref ref-type="corresp" rid="cor1"/>
          </contrib>
          <aff id="aff1">Gopa Iyer, Hikmat Al-Ahmadie, Nikolaus Schultz, Aphrothiti J. Hanrahan, Irina Ostrovnaya, Arjun V. Balar, Philip H. Kim, Oscar Lin, Nils Weinhold, Chris Sander, Emily C. Zabor, Manickam Janakiraman, Ilana R. Garcia-Grossman, Adriana Heguy, Agnes Viale, Bernard H. Bochner, Victor E. Reuter, Dean F. Bajorin, and David B. Solit, Memorial Sloan-Kettering Cancer Center; Victor E. Reuter, Dean F. Bajorin, and David B. Solit, Weill Medical College, Cornell University, New York, NY; Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and Barry S. Taylor, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA.</aff>
        </contrib-group>
        <author-notes>
          <corresp id="cor1">Corresponding author: David B. Solit, MD, Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: <email>solitd@mskcc.org</email>.</corresp>
          <fn fn-type="conflict">
            <p>Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="ppub">
          <day>1</day>
          <month>9</month>
          <year>2013</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>29</day>
          <month>7</month>
          <year>2013</year>
        </pub-date>
        <volume>31</volume>
        <issue>25</issue>
        <issue-id pub-id-type="pmc-issue-id">226755</issue-id>
        <fpage>3133</fpage>
        <lpage>3140</lpage>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>09</month>
              <year>2014</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>09</month>
              <year>2014</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2014-09-01 00:12:50.753">
              <day>01</day>
              <month>09</month>
              <year>2014</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>Â© 2013 by American Society of Clinical Oncology</copyright-statement>
          <copyright-year>2013</copyright-year>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="zlj3133.pdf"/>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="zlj02513003133.pdf"/>
        <abstract>
          <sec>
            <title>Purpose</title>
            <p>We sought to define the prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer to serve as a platform for therapeutic drug discovery.</p>
          </sec>
          <sec>
            <title>Patients and Methods</title>
            <p>An integrative analysis of 97 high-grade bladder tumors was conducted to identify actionable drug targets, which are defined as genomic alterations that have been clinically validated in another cancer type (eg, <italic toggle="yes">BRAF</italic> mutation) or alterations for which a selective inhibitor of the target or pathway is under clinical investigation. DNA copy number alterations (CNAs) were defined by using array comparative genomic hybridization. Mutation profiling was performed by using both mass spectroscopy-based genotyping and Sanger sequencing.</p>
          </sec>
          <sec>
            <title>Results</title>
            <p>Sixty-one percent of tumors harbored potentially actionable genomic alterations. A core pathway analysis of the integrated data set revealed a nonoverlapping pattern of mutations in the RTK-RAS-RAF and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathways and regulators of G<sub>1</sub>-S cell cycle progression. Unsupervised clustering of CNAs defined two distinct classes of bladder tumors that differed in the degree of their CNA burden. Integration of mutation and copy number analyses revealed that mutations in <italic toggle="yes">TP53</italic> and <italic toggle="yes">RB1</italic> were significantly more common in tumors with a high CNA burden (<italic toggle="yes">P</italic> &lt; .001 and <italic toggle="yes">P</italic> &lt; .003, respectively).</p>
          </sec>
          <sec>
            <title>Conclusion</title>
            <p>High-grade bladder cancer possesses substantial genomic heterogeneity. The majority of tumors harbor potentially tractable genomic alterations that may predict for response to target-selective agents. Given the genomic diversity of bladder cancers, optimal development of target-specific agents will require pretreatment genomic characterization.</p>
          </sec>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
